An Open-Label Study to Evaluate the Safety of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) in Subjects on Concomitant Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Trial Profile

An Open-Label Study to Evaluate the Safety of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) in Subjects on Concomitant Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Oritavancin (Primary)
  • Indications Gram-positive infections; Skin infections
  • Focus Adverse reactions
  • Sponsors The Medicines Company
  • Most Recent Events

    • 09 Sep 2016 Status changed from recruiting to completed.
    • 17 Feb 2016 Planned number of patients changed from 25 to 40 as reported by ClinicalTrials.gov.
    • 17 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top